LAS VEGAS, NV -- (MARKET WIRE) -- October 23, 2006 -- Results of a secondary analysis of two pivotal studies were presented today at the 71st Annual Meeting of the American College of Gastroenterology (ACG), and showed that 60 percent of patients treated with AMITIZA™ (lubiprostone) experienced a spontaneous bowel movement (SBM) within 24 hours of treatment, and 80 percent experienced a SBM within 48 hours of treatment. Additionally, AMITIZA, the first selective chloride channel activator approved by the FDA for the treatment of chronic idiopathic constipation in adults, showed improvement in long-term symptom relief of this disorder with significant improvements in constipation severity, abdominal bloating and discomfort for up to 12 months.
